Coherus BioSciences (NASDAQ:CHRS – Get Free Report) is scheduled to release its earnings data after the market closes on Thursday, August 8th. Analysts expect Coherus BioSciences to post earnings of ($0.21) per share for the quarter.
Coherus BioSciences (NASDAQ:CHRS – Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.33). The firm had revenue of $77.06 million for the quarter, compared to analyst estimates of $102.00 million. During the same quarter last year, the firm posted ($0.89) EPS. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Coherus BioSciences Stock Down 4.5 %
CHRS traded down $0.07 during trading on Friday, reaching $1.37. 167,012 shares of the company’s stock were exchanged, compared to its average volume of 2,764,547. Coherus BioSciences has a fifty-two week low of $1.25 and a fifty-two week high of $5.47. The business has a 50 day moving average price of $1.66 and a 200 day moving average price of $2.08. The company has a market capitalization of $156.61 million, a P/E ratio of -1.83 and a beta of 0.60.
Analysts Set New Price Targets
Get Our Latest Stock Report on CHRS
About Coherus BioSciences
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
Featured Articles
- Five stocks we like better than Coherus BioSciences
- 3 Best Fintech Stocks for a Portfolio Boost
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- The How and Why of Investing in Gold Stocks
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
- What are earnings reports?
- Chevron Stock Dips as Earnings Miss Highlights Merger Uncertainty
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.